Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Clélia Mathieu"'
Autor:
Marie‐Charlotte Diringer, Pierre Coliat, Clélia Mathieu, Nina Laurent, Carole Mura, Mainak Banerjee, Chen Zhu, Anna Grabowska, Alison Ritchie, Philip Clarke, Alexandre Bernard, Claire Vit, Hélène Burckel, Georges Noel, Peter Harvey, Xavier Pivot, Alexandre Detappe
Publikováno v:
Small. 19:2370078
Autor:
Marie‐Charlotte Diringer, Pierre Coliat, Clélia Mathieu, Nina Laurent, Carole Mura, Mainak Banerjee, Chen Zhu, Anna Grabowska, Alison Ritchie, Philip Clarke, Alexandre Bernard, Claire Vit, Hélène Burckel, Georges Noel, Peter Harvey, Xavier Pivot, Alexandre Detappe
Publikováno v:
Small. 19:2205961
Improving the tumor reoxygenation to sensitize the tumor to radiation therapy is a cornerstone in radiation oncology. Here, the pre-clinical development of a clinically transferable liposomal formulation encapsulating trans sodium crocetinate (NP TSC
Autor:
Xavier Pivot, Eloise Thomas, P. Peter Ghoroghchian, Clélia Mathieu, Vincent Mittelheisser, Alexandre Detappe, Patricia Moreno-Gaona, François Lux, Olivier Tillement
Publikováno v:
Advanced Healthcare Materials
Advanced Healthcare Materials, Wiley, 2021, pp.2101565. ⟨10.1002/adhm.202101565⟩
Advanced Healthcare Materials, Wiley, 2021, pp.2101565. ⟨10.1002/adhm.202101565⟩
Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for 18 F-FDG-directed and combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562891159770cfa2d35fdca4038d0770
https://hal.archives-ouvertes.fr/hal-03469640
https://hal.archives-ouvertes.fr/hal-03469640
Publikováno v:
Cancer Drug Resistance
Cancer Drug Resistance, OAE Publishing Inc., 2019, ⟨10.20517/cdr.2019.26⟩
Cancer Drug Resistance, OAE Publishing Inc., 2019, ⟨10.20517/cdr.2019.26⟩
Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the load
Autor:
François Lux, Cédric Boura, Mickaël Gries, Noémie Thomas, Thibaut Peterlini, Régis Vanderesse, Olivier Tillement, Céline Frochot, Ludovic Colombeau, Eloise Thomas, Muriel Barberi-Heyob, Clélia Mathieu
Publikováno v:
International Conference on Porphyrins and Phthalocyanines, ICCP-10
International Conference on Porphyrins and Phthalocyanines, ICCP-10, Jul 2018, Munich, Germany
International Journal of Nanomedicine
International Journal of Nanomedicine, Dove Medical Press, 2017, 12, pp.7075-7088. ⟨10.2147/IJN.S141559⟩
International Conference on Porphyrins and Phthalocyanines, ICCP-10, Jul 2018, Munich, Germany
International Journal of Nanomedicine
International Journal of Nanomedicine, Dove Medical Press, 2017, 12, pp.7075-7088. ⟨10.2147/IJN.S141559⟩
Eloïse Thomas,1 Ludovic Colombeau,2 Mickaël Gries,3,4 Thibaut Peterlini,3,4 Clélia Mathieu,1 Noémie Thomas,3,4 Cédric Boura,3,4 Céline Frochot,2 Régis Vanderesse,5 François Lux,1 Muriel Barberi-Heyob,3,4 Olivier Tillement1 1Université Lyon,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::851b46eea1baefe512cd48a7ae0e46d8
https://hal.archives-ouvertes.fr/hal-01845326
https://hal.archives-ouvertes.fr/hal-01845326